TCRX earnings date and last-quarter result: last quarter beat, P/E -0.94. Updated 2026-07-23.
TScan Therapeutics (TCRX) Research Hub
TScan Therapeutics (TCRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 0.1897 USD (-6.64%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.94, market cap 0.06B. This hub links to the full technical, earnings and options research available for TCRX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.1897 USD (-6.64%) |
| 52-week range | 0.18 USD – 1.26 USD |
| Trend regime | Range |
| 14-day RSI | 27.8 (Oversold) |
| Trailing P/E | -0.94 |
| Market cap | 0.06B |
| Dividend yield | 0.00% |
Available research for TCRX
Covered Call on TCRX: how it works, illustrative setup around the real 0.1897 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TCRX: how it works, illustrative setup around the real 0.1897 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TCRX: how it works, illustrative setup around the real 0.1897 USD price, max profit/loss, breakeven and when to use it. Educational.
TCRX technical analysis: range, last 0.1897 USD, RSI 27.8, 52w range 0.18 USD–1.26 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is TCRX in?
TScan Therapeutics (TCRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TCRX in an uptrend or downtrend?
As of 2026-10-26, TCRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TCRX's trailing P/E ratio?
TCRX's trailing P/E is -0.94, with a market cap of 0.06B. See the earnings research page for full valuation detail.